An Objectives, Indications, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Toxicity and Healthcare Team Outcomes of Lamotrigine

Background: Originally defined as an antiepileptic drug, lamotrigine (LMT) is a phenyltriazine derivative. Objective: It is the objective of this literature review to assess the clinical epidemiological profile, pathological mechanisms, and management of movement disorders associated with lamotrigine. Methods: Two reviewers without language restrictions found and evaluated pertinent records in six databases. Exclusions were made for reports indicating the usage of LMT only caused tremor or ataxia. Results: A total of 108 cases from 19 countries were evaluated in 48 reports. Nineteen tics, twenty-one dyskinesias, fourteen myoclonus, thirteen parkinsonism, ten dystonia, and one stuttering were among the movement disorders linked to LMT that were discovered. Ten cases of akathisia, four cases of myoclonus, four cases of cerebellar syndromes, one case of hypertonia, one case of dyskinesia, and an undetermined number of cases of dystonia were among the cases. The reported age ranged from 1.574 years to 33.34 years on average. Epilepsy was the most prevalent LMT indication, while men were the most common sex. At the commencement of the movement condition, the average LMT dosage was 228 mg. In 81% of cases, the onset of movement disturbance occurred within 6 months of the start of LMT. In 83% of cases, the recovery period from LMT cessation was less than one month. LMT withdrawal was the most widely used management strategy. Conclusions: Movement disorder start, and recovery times are rarely described, and most instances in the literature did not provide a clear image of the individual. We think that a dose adjustment depending on the advantages and side effects, carefully considered case by case, can be made prior to cessation of LMT.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-04-14
DOI
https://doi.org/10.5281/zenodo.19564567
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An Objectives, Indications, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Toxicity and Healthcare Team Outcomes of Lamotrigine

Ramanjaneyulu D.V., Muralinath E., Karthik Jayanyj Y., Srinivas G. et al.
Zenodo (CERN European Organization for Nuclear Research)
Epilepsy research and treatment
article

An Objectives, Indications, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Toxicity and Healthcare Team Outcomes of Lamotrigine

Ramanjaneyulu D.V., Muralinath E., Karthik Jayanyj Y., Srinivas G., Guruprasad M.
article en

Abstract

Background: Originally defined as an antiepileptic drug, lamotrigine (LMT) is a phenyltriazine derivative. Objective: It is the objective of this literature review to assess the clinical epidemiological profile, pathological mechanisms, and management of movement disorders associated with lamotrigine. Methods: Two reviewers without language restrictions found and evaluated pertinent records in six databases. Exclusions were made for reports indicating the usage of LMT only caused tremor or ataxia. Results: A total of 108 cases from 19 countries were evaluated in 48 reports. Nineteen tics, twenty-one dyskinesias, fourteen myoclonus, thirteen parkinsonism, ten dystonia, and one stuttering were among the movement disorders linked to LMT that were discovered. Ten cases of akathisia, four cases of myoclonus, four cases of cerebellar syndromes, one case of hypertonia, one case of dyskinesia, and an undetermined number of cases of dystonia were among the cases. The reported age ranged from 1.574 years to 33.34 years on average. Epilepsy was the most prevalent LMT indication, while men were the most common sex. At the commencement of the movement condition, the average LMT dosage was 228 mg. In 81% of cases, the onset of movement disturbance occurred within 6 months of the start of LMT. In 83% of cases, the recovery period from LMT cessation was less than one month. LMT withdrawal was the most widely used management strategy. Conclusions: Movement disorder start, and recovery times are rarely described, and most instances in the literature did not provide a clear image of the individual. We think that a dose adjustment depending on the advantages and side effects, carefully considered case by case, can be made prior to cessation of LMT.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 6%
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

An Objectives, Indications, Mechanism of Action, Administration, Adverse Effects, Contra Indications, Toxicity and Healthcare Team Outcomes of Lamotrigine — Ramanjaneyulu D.V., Muralinath E., et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS